MG
EVMN

Michael Gelband’s Evommune Inc EVMN Stock Holding History

Michael Gelband’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$202K Sell
15,227
-78,686
-84% -$1.83M ﹤0.01% 1421
2026
Q1 		$2.16M Buy
+93,913
New +$2.12M 0.02% 756

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Michael Gelband's EVMN Position: Q2 2026 in Review

Michael Gelband reduced its Evommune Inc (EVMN) stake by 84% in Q2 2026, selling an estimated $1.83M and leaving 15,227 shares worth $202K. The position accounts for ﹤0.01% of the portfolio, ranked #1421.

Michael Gelband first reported a position in EVMN in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.16M in Q1 2026. 104 funds tracked by Wall St. Rank hold EVMN as of Q2 2026.

  • Michael Gelband held 15,227 shares of Evommune Inc worth $202K as of Q2 2026.
  • Michael Gelband sold 78,686 Evommune Inc shares in Q2 2026, an estimated $1.83M.
  • Evommune Inc made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1421 holding.
  • Michael Gelband first reported a position in Evommune Inc in Q1 2026 and has held it in 2 quarters since.
  • Michael Gelband's Evommune Inc position peaked at $2.16M in Q1 2026.
  • 104 funds tracked by Wall St. Rank held Evommune Inc as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.